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Abstract
Background: To document albuminuria prevalence and its associated factors in Aboriginal and Torres Strait Islander
(TSI) adults with high renal and metabolic risks from 19 rural and remote north Queensland communities.
Methods: One thousand nine hundred seventy-one indigenous adults were enrolled in 1998 and 566 completed
follow up in 2007 in this population-based study. Measurements included weight, waist circumference (WC), blood
pressure (BP), fasting glucose, lipids, gamma-glutamyltransferase (GGT), urinary albumin creatinine ratio (UACR),
smoking, alcohol intake and physical activity (PA). Albuminuria was defined as an UACR > =2.5 g/mol in males
and > =3.5 g/mol in females. The association between albuminuria and biomedical factors was assessed with
generalised linear modelling.
Results: Baseline albuminuria prevalence was 19.7 % (95 % CI: 18.0–21.6 %). Follow up prevalence was 42.4 %
(95 % CI: 38.4–46.5 %) among the 566 adults having the 2nd UACR measurements. Follow-up albuminuria was
associated with fasting glucose of 5.4 mmol/L (OR 2.5, 95 % CI 1.5–4.2), GGT tertiles in a dose-response manner
(OR 2.0 for 2nd and 3.7 for 3rd tertile, p for trend <0.001), and abdominal overweight and obesity (OR 2.1, 95 % CI
1.1–3.9 and 5.4, 95 % CI: 2.2–13.5 respectively). Aboriginal people with diabetes were three times more likely of
having albuminuria compared to TSI counterparts, while TSI smokers had twice the likelihood (95 % CI 1.2–3.2).
At both baseline and follow up, albuminuria was more prevalent among older participants.
Conclusions: Indigenous Australians in north Queensland are at high risk of albuminuria. Overweight and obesity,
glycaemia, increased GGT, and smoking were associated with albuminuria at baseline and/or follow up.
Keywords: Albuminuria prevalence, Australian Indigenous populations, Overweight and obesity, Blood glucose and
diabetes, Gamma-glutamyltransferase, Smoking
Background
Albuminuria is a pathological condition with excessive
leakage of protein into the urine. It is an indicator of
kidney damage and is an early manifestation of impaired
kidney function leading to chronic kidney disease
(CKD). CKD is becoming a worldwide public health
problem [1] where individuals with kidney failure re-
quire dialysis or transplantation that poses a substantial
pressure on the health-care system [2]. With an aging
population and increasing prevalence of diabetes and
other chronic diseases, early detection and appropriate
management of CKD becomes important [3]. From a
public health perspective, screening for albuminuria to
prevent CKD and cardiovascular disease (CVD) is feas-
ible and cost effective in high risk populations [4–7],
based on the consistent results among large population
studies that albuminuria and proteinuria strongly and in-
dependently predict the risk of CKD progress, CVD, and
all cause-mortality [8–10].
The Australian Diabetes, Obesity and lifestyle Study
(AusDiab) reported a prevalence of micro albuminuria and
macro albuminuria, defined as UACR > =2.5 g/mol for
males and > =3.5 g/mol for females in a spot urine test,
among over 25 year old Australians in 2000 as 6.0 % and
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0.6 % respectively [11]. A five-year follow up of the same
population showed a 0.8 % annual incidence of albuminuria
[12]. Aboriginal and TSI people are at substantially greater
risk of having poorer health outcomes including CKD and
associated hospitalization and deaths compared to non-
Indigenous Australians [13]. Among screened volunteers
from an isolated Northern Territory (NT) Aboriginal com-
munity during 1992–1995, 26 % of adults had micro albu-
minuria and 24 % had overt albuminuria [14], similar to the
rate from screening surveys conducted in Aboriginal com-
munities in South Australia (SA), Western Australia (WA)
and Queensland (QLD) during 1995–1997 [15, 16]. We
have shown that albuminuria predicts incidence of diabetes,
hypertension, and coronary heart diseases among Indigen-
ous adults in Far North Queensland [17–20]. Therefore,
understanding albuminuria and its predictors is important
in preventing and managing effectively these morbidities.
However, the associated factors of albuminuria among Indi-
genous Australians are not well reported, and to date CKD
has largely been focused on the evaluation of end-stage kid-
ney disease (ESKD) using clinical data [13].
Here we aim to document the prevalence of albumin-
uria and its associated factors in two Indigenous popula-
tions from north Queensland.
Methods
Study population
This study included a subgroup of 1971 Indigenous par-
ticipants aged over 18 years in far north Queensland in
the “Well Person’s Health Check” (WPHC). WPHC was
a population based wellness screening program in 19
rural and remote Indigenous communities across three
health districts during 1998–2000. Methods for this
cross sectional study have been reported in detail else-
where [21]. Briefly, all Indigenous residents of the com-
munities aged 13 years and over were invited to attend a
health check via local health services, community coun-
cils, and community groups. Based on the local census
data, the study achieved a participation rate of 44.5 %
with greater participation noted in smaller communities.
The follow-up data were collected during 2004–2007.
Participants overall were not different demographically
from the age and sex distribution of the Australian Indi-
genous population as a whole. Written informed consent
was obtained from participants. The study protocols
were approved by the Cairns Base Hospital Human
Research Ethics Committee with support from the peak
Indigenous Health Organizations, Apunipima Cape York
Health Council and the Torres Strait and Northern
Peninsula Area Health Council.
Measurements
Urine specimens provided by participants in sterile
50 mL containers were from the first morning void or a
sample at least two hours from the most recent void.
Dipstick urinalysis (Combur-test, Roche) tested the sam-
ples for protein, pH, nitrites, leucocytes and blood.
UACR was measured by immunoassay in g/mol in
Cairns Base Hospital. Albuminuria was defined as having
UACR > =2.5 g/mol in males and > =3.5 g/mol in females
based on a single urine test.
Participants in light clothes were weighed to the near-
est 0.1 kg. Height and WC were recorded to the nearest
centimetre with the latter measured by the same techni-
cian at the level of the umbilicus. BP was the average of
three measurements taken sitting after 10 min rest using
a Dinamap model 800 automated blood pressure moni-
tor (Critikon; Tampa FL, US). PA was self-reported and
was categorized using the WHO criteria in which
‘enough’ means doing moderate to vigorous physical ac-
tivity for more than 30 min/day for 5 days in the week
before the survey. Daily number of cigarettes smoked
and alcohol intake was also self-reported.
GGT, fasting total cholesterol, high density lipoprotein
cholesterol (HDLC), triglycerides, and glucose were
measured on fasting blood. GGT was measured using
the kinetic photometric procedure with Cobas Integra
800 (Roche Diagnostics, www.roche-diagnostics.us/).
Blood lipids and blood glucose were measured using
photometric enzyme endpoint assay with Cobas Integra
700/400 (Roche Diagnostics, www.roche-diagnostics.us/).
Abdominal overweight was defined using WHO criteria
as WC greater than 80 cm in females and 94 cm in males
and obesity as greater than 88 cm in female and 102 in
male. Baseline hypertension was ascertained either by de-
tection of high BP at examination (measured BP > =140/
90 (mmHg) or previous confirmed diagnosis or currently
prescribed antihypertensive medication (by medical record
review). Dyslipidaemia was defined as having triglycer-
ides > =2.0 mmol/L or HDLC <1.0 mmol/L recommended
by the National Heart Foundation. Diabetes was defined
as either clinical diagnosis verified by the participants’
medical records, a 2 h oral glucose tolerance test, or fast-
ing blood glucose level >7.0 mmol/L.
Analysis
Prevalence of albuminuria at baseline and follow up was
estimated using UACR measurements at two time points
respectively, and its 95 % confidence interval was computed
using the binomial distribution. Prevalence was compared
by baseline characteristics including age group (<35 years
vs > =35 years), sex, ethnicity, hypertension, fasting glucose
or diabetes, blood lipids, GGT categories, smoking and
drinking habits. The association between albuminuria at
follow up and biomedical factors were explored using Gen-
eralised Linear Model with family of “binomial” and link of
“logit”. Prevalence rate ratio (OR) was adjusted for age, sex
and ethnicity. The analysis was carried out using STATA 13
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(STATAcorp, College Station, Texas, USA) and significance
level was set at two-sided P < 0.05.
Results
Among 1971 Indigenous participants aged 18 years and
over (mean age 38.7 years) with available UACR mea-
surements in the 19 communities, 64 % were over-
weight/obese. The prevalence of hypertension was 31 %
and diabetes was 17 %. 58 % reported smoking and 70 %
self-reported as alcohol drinkers. 389 had albuminuria at
baseline (19.7 %, 95 % CI: 18.0–21.6 %). Those with al-
buminuria were more likely to be older, TSIs but not
different by sex (Table 1). Overweight/obesity, and
higher BP, glucose, and GGT were associated with base-
line albuminuria independent of age, sex and ethnicity.
Figure 1 showed participants during the follow up
period (1998–2007) by baseline albuminuria categories. In
total, 566 people had the 2nd UACR measurements, 182
had died, 427 had moved away from the communities, 21
were in prison, and 775 left with no reason recorded. The
baseline characteristics by follow up status are summa-
rized in the Additional file 1: Table S1. Briefly, compared
to those who completed follow up, those not followed up
were significantly younger, more likely to be Aboriginal
Table 1 Baseline characteristics of Indigenous adults in 19 communities from North Queensland 1998–2000 by albuminuria at baseline
Albuminuria No = 1582 Albuminuria Yes = 389 Total N = 1971
Mean or % (95% CI) Mean or % (95% CI) Mean or % (95% CI)
Age (Years) * 36.8 (36.1-37.5) 46.5 (45.0-48.0) 38.7 (38.1-39.4)
Female % 50.6 (48.2-53.1) 48.8 (43.9-53.8) 50.3 (48.1-52.5)
Aboriginal % * 54.0 (51.5-56.4) 43.4 (38.6-48.4) 51.9 (49.7-54.1)
WC (CM) * 95.8 (95.0-96.6) 104.4 (102.8-106.0) 97.5 (96.8-98.2)
Abdominal overweight and obesity * %
Overweight 19.6 (17.5-21.8) 19.0 (14.8-23.9) 19.5 (17.6-21.5)
Obesity 41.4 (38.8-44.1) 58.3 (52.5-63.8) 44.4 (42.0-46.8)
BMI (kg/m2) * 27.8 (27.5-28.1) 30.4 (29.6-31.1) 28.3 (28.0-28.6)
BMI % *
25-29.9 27.0 (24.9-29.3) 25.2 (21.1-29.9) 26.7 (24.8-28.7)
> = 30 34.4 (32.1-36.8) 50.9 (45.9-55.9) 37.7 (35.5-39.8)
SBP (mmHg) * 129.2 (128.3-130.1) 140.8 (138.7-142.8) 131.5 (130.6-132.3)
DBP (mmHg) * 71.0 (70.3-71.7) 77.5 (76.2-78.8) 72.3 (71.7-72.9)
Hypertension % * 26.4 (24.3-28.6) 49.9 (44.9-54.8) 31.0 (29.0-33.1)
Glucose (mmol/L) * 5.5 (5.4-5.7) 7.0 (6.7-7.4) 5.8 (5.7-6.0)
Diabetes % * 12.4 (10.9-14.1) 35.2 (30.6-40.1) 16.9 (15.3-18.6)
Cholesterol (mmol/L) * 4.97 (4.92-5.02) 5.13 (5.02-5.24) 5.00 (4.96-5.05)
Triglycerides (mmol/L) * 1.87 (1.79-1.94) 2.12 (1.95-2.29) 1.92 (1.85-1.99)
HDL (mmol/L) 1.12 (1.11-1.14) 1.18 (1.15-1.20) 1.13 (1.12-1.15)
Dyslipidaemia % 46.8 (44.3-49.3) 49.5 (44.4-54.5) 47.3 (45.1-49.5)
GGT (IU) * 50.2 (47.0-53.4) 57.5 (51.6-63.3) 51.6 (48.8-54.5)
GGT > 50 % * 28.7 (26.5-31.0) 38.2 (33.4-43.2) 30.6 (28.5-32.7)
Smoker % * 60.4 (58.0-62.8) 49.2 (44.3-54.2) 58.2 (56.0-60.4)
Drinking status %
Moderate 23.4 (21.4-25.6) 20.4 (16.6-24.7) 22.8 (21.0-24.7)
Risky 49.3 (46.8-51.8) 46.8 (41.8-51.9) 48.8 (46.6-51.1)
PA sufficient % 25.6 (23.5-27.8) 18.8 (15.2-23.0) 24.3 (22.4-26.2)
*P < 0.05 from ttest or chi square test or corresponding non-parametric tests
Abdominal overweight was defined using WHO criteria as WC greater than 80 cm in females and 94 cm in males and obesity as greater than 88 cm in
female and 102 in male
Hypertension was ascertained either by detection of high BP at examination (measured BP > =140/90 (mmHg) or previous confirmed diagnosis or currently
prescribed antihypertensive medication (by medical record review)
Diabetes was defined as either clinical diagnosis verified by the participants’ medical records or a 2 hour oral glucose tolerance test, or fasting blood
glucose level >7.0 mmol/L
Dyslipidaemia was defined as having triglycerides > =2.0 mmol/L or HDLC <1.0 mmol/L recommended by National Heart Foundation
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with significantly healthier biomedical measurements
including BMI, systolic BP, and fasting blood glucose, but
were also more likely to smoke tobacco, and/or drink
alcohol. Among participants with baseline albuminuria,
more had died or did not complete follow up, and fewer
were imprisoned or moved away from the communities.
People having the 2nd UACR test were evenly distributed
by baseline albuminuria categories.
Among the complete cohort, 201 were Aboriginal, 303
were TSI people and 62 were joint descendants. Aborigi-
nal people had higher diastolic BP, triglycerides, and
GGT, and a higher percentage of risky drinkers, but
lower WC, BMI, and fasting glucose than the TSI
participants. The demographic and biomedical charac-
teristics of the complete cohort were similar to those
among baseline population (Additional file 2: Table S2).
At the follow up, 133 new cases of albuminuria devel-
oped among those with normal UACR at baseline, while
107 baseline cases remained as albuminuria. Twenty-
eight went normal at the follow up (Fig. 1). The mean
UACR of the 28 cases (12 of whom were females) was
1.2 g/mol at follow up. To sum up, a total of 240 albu-
minuria cases were identified among 566 participants
giving an overall follow up prevalence of albuminuria
42.4 % (95 % CI: 38.8–46.5 %). The prevalence of albu-
minuria was higher than the baseline as shown in Fig. 2.
Fig. 2 Albuminuria prevalence among Indigenous adults in 19 rural and remote communities in North Queensland 1998–2007
Fig. 1 UACR measurements and albuminuria among the participants at baseline and follow up surveys during 1998–2007
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Table 2 shows the biomedical and behavioral characteris-
tics of the complete cohort by follow up albuminuria. Par-
ticipants with albuminuria at follow up were older or had
higher BMI, BP, cholesterol, triglycerides, and GGT. Follow
up albuminuria was not associated with drinking and PA
and it was not significantly different by sex and ethnicity.
As shown in Table 3, in both Indigenous populations,
diabetes was strongly associated with follow-up albu-
minuria (OR 2.7, 95 % CI 1.8–4.2) after adjustment for
age, sex, and ethnicity. Further analysis showed within
the normal glucose range, that those with a baseline
fasting glucose of more than 5.4 mmol/L had 2.5 times
higher risk of albuminuria at follow up (OR: 2.5, 95 %
CI: 1.5–4.2) compared to less than 4.7 mmol/L.
Baseline GGT > = 50 IU was associated with increased
risk of albuminuria by 2.6 times (95 % CI 1.7-3.9). A
dose responsive effect of GGT with albuminuria was de-
tected. Specifically, a GGT level of 25–47 IU associated
with 2-fold prevalence of albuminuria (95 % CI: 1.3–3.1)
and a level of > =48 by 3.7 times (95 % CI: 2.2–6.2) com-
pared to a level of <25 IU (p for trend <0.001). Abdom-
inal overweight and obesity was associated with
albuminuria at follow up by 2.1 (95 % CI: 1.1–3.9) and
5.4 (95 % CI: 2.2–13.5) respectively.
Table 2 Baseline characteristics of Indigenous adults in 19 communities from North Queensland by albuminuria at follow up
Albuminuria No = 326 Albuminuria Yes = 240
Mean or % (95% CI) Mean or % (95% CI)
Age (Years) * 38.4 (37.0-39.8) 44.7 (43.0-46.3)
Female % 52.1 (46.7-57.5) 44.6 (38.4-51.0)
Aboriginal % 32.8 (27.9-38.1) 39.2 (33.2-45.5)
WC (CM) * 97.9 (96.1-99.8) 105.8 (103.8-107.8)
Abdominal overweight and obesity * %
Overweight 18.5 (14.4-23.6) 19.6 (14.3-26.4)
Obesity 46.2 (40.3-52.1) 58.3 (50.7-65.6)
BMI (kg/m2) * 28.7 (27.9-29.6) 31.0 (30.1-31.8)
BMI % *
25-29.9 26.6 (22.1-31.7) 22.2 (17.3-27.9)
> = 30 40.2 (35.0-45.7) 55.2 (48.8-61.4)
SBP (mmHg) * 130.0 (128.0-131.9) 137.3 (135.0-139.6)
DBP (mmHg) * 71.5 (70.1-73.0) 75.3 (73.6-77.1)
Hypertension % * 31.4 (26.6-36.7) 44.2 (38.0-50.5)
Glucose (mmol/L) * 5.5 (5.3-5.8) 6.8 (6.3-7.2)
Diabetes % * 15.0 (11.5-19.4) 35.4 (29.6-41.7)
Cholesterol (mmol/L) * 4.9 (4.8-5.0) 5.3 (5.2-5.5)
Triglycerides (mmol/L) * 1.7 (1.5-1.8) 2.4 (2.2-2.7)
HDL (mmol/L)* 1.12 (1.09-1.15) 1.08 (1.04-1.12)
Dyslipidaemia % * 42.3 (37.0-47.8) 60.0 (53.5-66.2)
GGT (IU) * 40.5 (36.0-45.0) 64.2 (53.2-75.3)
GGT > 50 % * 19.2 (15.2-23.9) 39.6 (33.4-46.1)
Smoker % 49.2 (43.8-54.7) 55.5 (49.1-61.7)
Drinking status %
Moderate 25.6 (21.1-30.8) 20.6 (15.9-26.2)
Risky 41.5 (36.1-47.0) 44.1 (37.9-50.5)
PA sufficient % 28.2 (23.6-33.4) 26.7 (21.4-32.6)
*P < 0.05 from ttest or chi square test or corresponding non-parametric tests
Abdominal overweight was defined using WHO criteria as WC greater than 80 cm in females and 94 cm in males and obesity as greater than 88 cm in
female and 102 in male
Hypertension was ascertained either by detection of high BP at examination (measured BP > =140/90 (mmHg) or previous confirmed diagnosis or currently
prescribed antihypertensive medication (by medical record review)
Diabetes was defined as either clinical diagnosis verified by the participants’ medical records or a 2 hour oral glucose tolerance test, or fasting blood
glucose level >7.0 mmol/L
Dyslipidaemia was defined as having triglycerides > =2.0 mmol/L or HDLC <1.0 mmol/L recommended by National Heart Foundation
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Aboriginal people having diabetes were 3 times more
likely than TSI diabetes patients to have albuminuria at
follow up. TSI smokers were twice as likely to have albu-
minuria compared to non-smokers, but this effect was
not demonstrated among Aboriginal participants.
Discussion
This study found a high baseline prevalence of albumin-
uria (20 %) among adults from rural and remote com-
munities in north Queensland, especially among those
aged over 25 years. And baseline albuminuria was asso-
ciated with features of the metabolic syndrome (BMI,
BP, dyslipidaemia and glucose) and higher GGT levels.
This is consistent with the prevalence and associated
factors reported in other Aboriginal communities in NT,
SA, WA, and QLD [14–16]. The prevalence is 3 times
higher than the prevalence found in the national non-
Indigenous sample (AusDiab) [11].
Indigenous people in rural and remote communities
had more than double the risk of follow up albumin-
uria at an early age compared contemporarily to the
non-Indigenous Australians from the AusDiab study,
similar to findings from an Aboriginal population in
the NT [22]. The prevalence at follow up was more
than twice of the baseline during a median 7 years of
follow up.
We found consistently that increased fasting glucose
or diabetes was associated with albuminuria at both oc-
casions. The baseline prevalence of diabetes/impaired
glucose tolerance in Indigenous population was be-
tween 3 and 5 times higher than the comparable rates
for non-Indigenous people in all age groups from
25 years and over [23]. We have reported that the dia-
betes incidence in this cohort was 4 times that of non-
Indigenous people and appeared to be increasing over
the estimates from a decade previously [17]. As albu-
minuria is a key early marker of future CKD and ESRD,
Indigenous Australians are at particularly high risk, and
evidence for effective primary care level management is
strong. Therefore early screening for albuminuria is
important in this population [24]. Our finding that ab-
dominal overweight and obesity predicted albuminuria
independently of diabetes is consistent with other co-
hort studies among south Asians and Chinese [25, 26].
Apart from secondary prevention of ESRD with drugs,
surgical intervention to reduce obesity has proved
Table 3 Biomedical factors associated with follow-up albuminuria among Indigenous adults in 19 communities from North
Queensland (OR and 95% CI)
Aboriginal TSI Overall
Crude Adjusteda Crude Adjusteda Crude Adjustedb
Abdominal overweight/obesity “No” as reference
Overweight 1.9 (0.8–4.3) 2.2 (0.9–5.6) 3.4 (1.2–9.9) 2.8 (0.9–8.4) 1.7 (1.0–3.0) 2.1 (1.1–3.9)
Obesity 2.3 (1.2–4.4) 5.7 (1.8–18.6) 4.2 (1.7–10.7) 8.8 (1.6–49.5) 2.0 (1.3–3.2) 5.4 (2.2–13.5)
GGT > =50 IU “<50” as reference
Yes 2.0 (1.1–3.6) 2.1 (1.1–4.1) 2.8 (1.6–5.1) 2.6 (1.4–5.0) 2.8 (1.9–4.1) 2.6 (1.7–3.9)
GGT tertiles “<25 IU” as reference
25–47 1.5 (0.7–3.4) 1.2 (0.5–2.9) 2.5 (1.4–4.3) 2.4 (1.3–4.3) 2.2 (1.4–3.3) 2.0 (1.3–3.1)
> = 48 2.5 (1.2–5.3) 2.3 (1.0–5.4) 4.2 (2.2–8.2) 4.2 (2.0–8.7) 4.0 (2.5–6.2) 3.7 (2.2–6.2)
Hypertension “<140/90 mmHg” as reference
Yes 2.2 (1.2–3.9) 1.6 (0.9–3.1) 1.4 (0.9–2.2) 1.0 (0.6–1.7) 1.7 (1.2–2.4) 1.2 (0.8–1.8)
Diabetes “No” as reference
Yes 6.1 (2.5–14.7) 5.8 (2.4–14.6) 2.5 (1.5–4.1) 2.0 (1.2–3.5) 3.1 (2.1–4.6) 2.7 (1.8–4.2)
Glucose tertiles “<4.7 mmol//L” as reference
4.7–5.3 1.8 (0.9–3.8) 1.7 (0.8–3.6) 1.5 (0.8–3.0) 1.2 (0.6–2.4) 1.4 (0.9–2.2) 1.4 (0.9–2.3)
> = 5.4 4.2 (2.0–9.1) 3.8 (1.7–8.4) 2.7 (1.4–5.2) 1.9 (0.9–3.9) 2.4 (1.5–3.8) 2.5 (1.5–4.2)
Current smoker “No” as reference
Yes 1.0 (0.6–1.8) 1.0 (0.6–1.9) 1.7 (1.1–2.7) 2.0 (1.2–3.2) 1.3 (0.9–1.8) 1.4 (1.0–2.0)
aadjusted for age and sex in each ethnic group, further adjusted for ethnicity in overall population
Abdominal overweight was defined using WHO criteria as WC greater than 80 cm in females and 94 cm in males and obesity as greater than 88 cm in
female and 102 in male
Hypertension was ascertained either by detection of high BP at examination (measured BP > =140/90 (mmHg) or previous confirmed diagnosis or currently
prescribed antihypertensive medication (by medical record review)
Diabetes was defined as either clinical diagnosis verified by the participants’ medical records or a 2 hour oral glucose tolerance test, or fasting blood
glucose level >7.0 mmol/L
Dyslipidaemia was defined as having triglycerides > =2.0 mmol/L or HDLC <1.0 mmol/L recommended by National Heart Foundation
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highly effective in reducing albuminuria incidence
among obese Swedish subjects [27]. The underlying
mechanisms may include renin-angiotensin-aldosterone
system activation, leptin, adiponectin, fetuin-A, and
adipose tissue inflammation, as factors that contribute
to glomerulonephritis, focal and segmental glomerulo-
sclerosis, and IgA nephropathy [28].
Tobacco smoking is highly prevalent among Indigenous
Australians and was associated with albuminuria at both
baseline and follow up. This finding is similar to other
studies in Europeans, Americans and Asians [29–31].
Smoking predicted albuminuria or proteinuria in the Fra-
mingham Offspring Cohort [32] and Japanese adults [33]
but not among the European PREVEND cohort [34].
GGT, as a marker of liver disease and alcohol intake
and as a biomarker of oxidative stress [35], was associ-
ated with albuminuria in a dose-responsive manner in
the two Indigenous populations after adjustment for
demographics, overweight and obesity, diabetes, hyper-
tension, and smoking and drinking habits. The results
were similar to the systematic review on the association
between GGT and albuminuria or CKD in both cross
sectional and follow up studies among Americans and
Koreans [36]. We have reported that GGT predicts
hypertension incidence [37] and is highly correlated with
overweight and obesity. Metabolic syndrome and alcohol
drinking magnifies the association between GGT and
metabolic components among this population [38, 39].
Further exploration of its association with cardiovascular
conditions and diabetes is needed to understand the
additional independent impact of GGT on albuminuria
found in this population for better risk evaluation or
stratification in Indigenous population.
Strengths of this study include a representative
community-based sample of both Aboriginal and TSI
populations and objective clinical measurements. TSIs are
the second group of Indigenous Australians who inhabit
the islands of Torres Strait as a part of Queensland. They
have a heavier phenotype and a healthier lifestyle com-
pared to Aborigines. The data collected in this study en-
abled us to compare albuminuria and its associated
biomedical factors between the two ethnic groups.
Although the risk profiles in the two populations are dif-
ferent, the albuminuria prevalence was not statistically dif-
ferent, partly due to the higher risk for Aboriginal people
given the same level of increased glucose or diabetes, and/
or less risk for Aboriginal smokers compared to TSIs, or
disproportionally increased loss of Aboriginal participants,
including those with baseline albuminuria.
Limitations should be noted. Firstly, the definition of
albuminuria was based on a single UACR measurement
due to the study design of screening a large general
population from communities with limited resources,
which could misclassify cases. The follow up data
showed a small number of baseline micro albuminuria
cases were normal at follow up. Secondly, the follow up
information was not completed to sufficiently facilitate
the estimation of the incidence rate, especially for those
who moved from the communities. Thirdly, a large
number of relatively healthier Aboriginal participants
lost contact at the follow up which could result in over-
estimate of the prevalence at follow up. Lastly, we could
not detail medical and family history, and some potential
confounders to explore albuminuria and its predictors.
For example, studies among Aboriginal Australians in
remote communities show that earlier infection is
strongly associated with kidney dysfunction in later life
[40, 41]. In spite of these, this study documented the
prevalence from a representative population for both
Aboriginal and TSI groups in rural and remote commu-
nities in North Queensland at baseline and the follow up
albuminuria in a selected group of high risk participants
including important biomedical factors.
Conclusions
The high prevalence of albuminuria in the Indigenous
Australian population was associated with excessive risk
of glycaemia, diabetes, obesity, increased GGT, or smok-
ing. Early screening and management of these factors
are essential to stem the tide of ESRD and CVD in this
population.
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